Acalabrutinib combined with venetoclax, with or without obinutuzumab, could lead to the FDA approval of the first all-oral frontline CLL therapy. The AMPLIFY clinical trial demonstrated that this combination therapy is very effective and well tolerated. The addition of the IV monoclonal antibody obinutuzumab (Gazyva) improves efficacy but at the cost of increased infection risk for those with chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL).
Dr. Jennifer Brown from Dana Farber, Boston, MA, led an international group of investigators in this large registration (for therapy approval) trial. She gave an oral presentation of the research at ASH, the American Society of Hematology Annual Meeting and Exposition, held in San Diego, CA, in December 2024.
Read the full article on CLL Society's website at: cllsociety.org/2025/01/amplify-trial-acalabrutinib-plus-venetoclax-for-cll/
__________________________________________________________________________________________
CLL Society Website: cllsociety.org/
Facebook: CLLsociety
Twitter: CllSociety
LinkedIn: www.linkedin.com/company/cll-society/